Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Lanifibranor (Primary)
- Indications Systemic scleroderma
- Focus Proof of concept; Therapeutic Use
- Acronyms FASST
- Sponsors Inventiva Pharma
- 18 Feb 2019 Primary endpoint has not been met. (Measurement of skin thickness by the Modified Rodnan Skin Score (MRSS)), according to an Inventiva Pharma media release.
- 18 Feb 2019 Results presented in an Inventiva Pharma media release.
- 21 Dec 2018 Status changed from active, no longer recruiting to completed.